[8-K] Kodiak Sciences Inc Reports Material Event

Rhea-AI Filing Summary

Kodiak Sciences Inc. disclosed in a Form 8-K dated August 13, 2025 that it published a press release reporting the company’s financial results for the quarter ended June 30, 2025 and related business highlights; that press release is attached as Exhibit 99.1 to this report.

The filing states the press release and information contained or incorporated herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference. The 8-K lists an Inline XBRL cover page as Exhibit 104 and is signed by Victor Perlroth, M.D., Chief Executive Officer. The company’s common stock trades under the ticker KOD on The Nasdaq Stock Market.

Positive

• Press release attached as Exhibit 99.1 reporting financial results for the quarter ended June 30, 2025
• Form 8-K filed on August 13, 2025 providing timely public disclosure of the press release
• Includes Inline XBRL cover page (Exhibit 104), supporting interactive data
• Signed by the CEO, indicating authorized corporate disclosure

Negative

• The 8-K does not include the text or numerical financial results; the filing only references the press release
• The press release is stated as not being "filed" under Section 18, limiting incorporation and Section 18 liability
• Insufficient information in this filing alone to evaluate financial performance or material changes

Insights

Financial Analyst

TL;DR: Kodiak filed an 8-K attaching a Q2 2025 results press release; the filing itself does not disclose the financial details.

The Form 8-K confirms the company published financial results and business highlights for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1, and that the release is not being "filed" for Section 18 liability or incorporation by reference. As the 8-K does not include the press release text or numeric results, this filing alone provides no quantitative data to update revenue, earnings, cash position, or guidance models. Investors and analysts must review Exhibit 99.1 to assess operating performance and any material changes relative to prior periods.

Corporate Governance Expert

TL;DR: The company followed disclosure protocol by filing an 8-K and attaching the press release; material implications cannot be judged from this notice alone.

The report documents timely disclosure procedures: the press release was attached as Exhibit 99.1 and the Inline XBRL cover page is included as Exhibit 104, and the report bears the CEO’s signature. The filing’s statement that the release is not "filed" under Section 18 is a standard legal qualifier limiting incorporation and liability. From a governance and disclosure-process perspective, the company satisfied procedural requirements; however, the absence of the press release content in the body of the 8-K prevents assessment of material corporate developments or financial impacts.

0001468748false00014687482025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Kodiak Sciences Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38682	27-0476525
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1250 Page Mill Rd
Palo Alto, California				94304
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 281-0850

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		KOD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended June 30, 2025 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release published by Kodiak Sciences Inc. dated August 13, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			KODIAK SCIENCES INC.
Date:	August 13, 2025	By:	/s/ Victor Perlroth
			Victor Perlroth, M.D. Chief Executive Officer

FAQ

When was the 8-K filed for Kodiak Sciences (KOD)?

The Form 8-K was filed on August 13, 2025.

Which quarter’s results does Kodiak’s 8-K reference?

The filing references financial results for the quarter ended June 30, 2025.

Where can I find the press release mentioned in the 8-K?

The press release is attached to the 8-K as Exhibit 99.1.

Is the press release considered "filed" under the Exchange Act?

No. The filing states the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except by specific reference.

Who signed the Form 8-K for Kodiak Sciences?

The report is signed by Victor Perlroth, M.D., Chief Executive Officer.

What exhibits are listed in the 8-K?

The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File).